Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure - Wikidata - awgldk - TriplyDB

Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure

Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure

http://www.wikidata.org/entity/Q28177421

about

The role of urotensin II in cardiovascular and renal physiology and diseases Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol Urotensin II in chronic liver disease: in vivo effect on vascular tone.The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.Evaluation of the effects of urotensin II and soluble epoxide hydrolase inhibitor on skin microvessel tone in healthy controls and heart failure patients.Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems Potential Clinical Implications of the Urotensin II Receptor Antagonists.Recent advances in the diagnosis of heart failure.Urotensin II Protects Cardiomyocytes from Apoptosis Induced by Oxidative Stress through the CSE/H2S Pathway Is plasma urotensin II concentration an indicator of myocardial damage in patients with acute coronary syndrome?Urotensin II: its function in health and its role in disease.An investigation into the expression and mechanism of action of urotensin II in chronic pressure-overloaded rat hearts Urotensin-II induces ear flushing in rats Urotensin-II and cardiovascular diseases.Therapeutic potential of blockade of the urotensin II system in systemic hypertension.Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma.Role of urotensin II and its receptor in health and disease.Urotensin II in cardiovascular regulation.Direct inotropic effects of exogenous and endogenous urotensin-II: divergent actions in failing and nonfailing human myocardium.Role of urotensin II in health and disease.The role of neuropeptides in adverse myocardial remodeling and heart failure.Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.Role of UTS2 gene in the genetic susceptibility to atrial fibrillation in the Chinese population.Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.Kidney is in trouble with mediators.Urotensin-II: More Than a Mediator for Kidney.Renal effects of human urotensin-II in rats with experimental congestive heart failure.The Role of Human Urotensin-II in Patients with Hypertrophic Cardiomyopathy.

P2860

Q24675590-1F5AAB11-765D-49D1-857E-6E1B56D8ECB5 Q28572971-36943DA7-9EDA-4FB3-94AE-52D33BD9414C Q28573864-D326829A-B9BA-49AB-8291-AA855C026063 Q33378279-6B2C5408-278C-4870-A8E5-835A7E895653 Q33599835-F96FA4A8-BD1E-4A17-97ED-9A09DD5A17DD Q34007711-03FFE18D-08F2-4281-9FF9-61469687367C Q34248766-9ABC45EF-8A6E-4BA7-9F31-D56E58CBF7AF Q35048941-BD0F9CE7-A00F-4C49-BDB8-02E7B1EB781B Q35100902-67CDEE9E-D044-48FC-81E8-4FEEFCCCDDFF Q35128456-D3D67A69-7489-4AA5-907A-B78A1B8F04CF Q35742271-D56A551D-EDB4-4864-8E2E-245D4A4E61DB Q35813861-672EF732-1F1D-44DF-A353-A902DF5705D7 Q36105692-0760BCC5-F902-4C35-AB07-55A5888F7AFB Q36121966-2D6DE478-616A-4A7A-95EC-A48491120522 Q36224889-2C804C43-95BA-4D93-B387-2E9319A42AD1 Q36357772-68ABE5A6-560E-4170-A487-924B02FC2445 Q36670684-F90415A7-19DF-489D-B1ED-2A47D2E1A809 Q36760529-5DBFC729-3160-4B20-8E31-5E8AE187B6B5 Q36800470-0D295FBF-0EDF-45DC-A4F9-012662C6A489 Q36902874-040759B4-4FF0-40CD-A5E1-1BD3A38E48DC Q37344439-3F2CAC27-74D7-4955-B3DF-772FCE28343F Q37394539-84F08DC9-F239-4BB0-BB03-E5E030351A36 Q37737495-8B8BC0A9-37A2-481C-B172-A30670384286 Q39093111-E3036C9E-8533-429E-9023-9BD996212C2D Q40430686-1A9C42E5-C595-46C3-95B1-413B82985A68 Q40950590-C8180192-6998-4DFC-A150-4CF37F962900 Q41819007-E2F3CDEF-99C5-4E52-871B-8FA4FAE80222 Q42280581-4AE1555A-E286-4B3F-A401-F7C4E12222D7 Q42418210-6CD8FC9A-94DE-45FA-A045-2DAC62602756 Q46882457-671DD775-EC43-40AB-9C00-23D5541768D5 Q47706645-AFBE3474-E0A7-41B4-B3DA-2C3BE7CC00FC

P2860

Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure

http://www.wikidata.org/entity/Q28177421

description

2003 nî lūn-bûn

@nan

2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure

@ast

Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure

@en

Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure

@nl

type

label

Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure

@ast

Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure

@en

Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure

@nl

prefLabel

Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure

@ast

Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure

@en

Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure

@nl

P1433

Q28177421-2EED294D-8655-4900-B31B-E0FD030015E0

P1476

Q28177421-5FCA11A5-32D7-4C5B-9647-89A5DA7654EB

P2093

Q28177421-05D8002A-8B54-498D-AFFC-B81FAFD9237F

Q28177421-08B8E4FB-4999-47AF-B533-A7A632D40965

Q28177421-206360DB-5F44-41C2-9348-835ADC3C6835

Q28177421-AC5C60CB-BD70-4B84-8E5B-839AEE87EEBF

Q28177421-B84DBEFA-6B3A-4A6E-93E4-FDA2FEFE033A

Q28177421-C62D29C7-E2C5-4329-BCDE-E390C90CE909

P2860

Q28177421-109BDD62-E7B8-4157-9BB0-08CED248E655

Q28177421-1307C3B0-03B6-40B9-A95D-399BA73A05EF

Q28177421-201E4DB9-0DA6-4912-8C7E-1C28FA18C6AB

Q28177421-263D10E4-E3DB-421F-89E2-13D446455BD7

Q28177421-33B233B0-5EC5-4A17-A4A1-A39709582680

Q28177421-38E5E37E-4CB2-46E5-9A09-2944CD4F0122

Q28177421-53BE6043-FE94-4029-976A-8BFC94A5A6BE

Q28177421-7DE90F45-482D-472E-97B0-BD8BFE2FB86C

Q28177421-98B15490-6A9C-479D-A497-980BA0A8F7F6

Q28177421-B42EADDB-3123-4D0D-BB6E-BC5589ED0F85

P304

Q28177421-C8E943EA-7498-4A98-A9E0-ADEB43C2553C

P31

Q28177421-7B26CD66-7594-45BC-A742-F4D9958688AE

P356

Q28177421-024BDA7A-8BBB-4DD4-8116-8C9944A33D94

P407

Q28177421-87D4682B-5BEE-476E-9C66-7DDADD5C1538

P433

Q28177421-89E9D949-99BF-4FBE-A76A-B2D23991337F

P478

Q28177421-7D269D26-E2BC-44E6-8758-3E69888732C3

P50

Q28177421-B5FB683C-E265-47ED-BD30-8B870A54D6BC

P577

Q28177421-C91F7565-2EA8-49FA-AE48-8D540E7D379C

P5875

Q28177421-5FABA58A-5D9E-40DC-877D-BDDA2D5CCE33

P698

Q28177421-296DA284-E1F7-46A5-AE48-E22F70FEA7F1

P921

Q28177421-E850E872-B831-4EBC-91C0-CB880ED664DE

P356

AJPHEART.00217.2003

P1433

American Journal of Physiology - Heart and Circulatory Physiology

P1476

Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure

@en

P2093

Andrew J Galbraith

http://www.w3.org/2001/XMLSchema#string

Deborah Meyers

http://www.w3.org/2001/XMLSchema#string

Fraser D Russell

http://www.w3.org/2001/XMLSchema#string

Nick Bett

http://www.w3.org/2001/XMLSchema#string

Peter Molenaar

http://www.w3.org/2001/XMLSchema#string

Philip Kearns

http://www.w3.org/2001/XMLSchema#string

P2860

Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord

Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1

Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure

Cardiostimulant effects of urotensin-II in human heart in vitro.

The new pulmonary arterial catheters. Right ventricular ejection fraction and continuous cardiac output.

Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure.

Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats.

Congestive heart failure and expression of myocardial urotensin II.

Relationship between endothelin-1 extraction in the peripheral circulation and systemic vascular resistance in patients with severe congestive heart failure.

P304

H1576-81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPHEART.00217.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

285

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10720561

http://www.w3.org/2001/XMLSchema#string

P698

12791592

http://www.w3.org/2001/XMLSchema#string

P921